Every Form 4 that Bio-Rad Laboratories, Inc. (BIO) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow BIO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BIO filings page.
BIO-RAD LABORATORIES, INC. (BIO) reported transactions by director Allison Schwartz involving restricted stock units (RSUs) and Class A common stock. On September 4, 2026, she received a grant of 719 RSUs, each representing one share of Class A common stock, vesting over four years. On September 5 and 6, a total of 320 RSUs vested and were converted into an equal number of Class A shares, with 116 shares delivered or withheld to cover the exercise price or tax liability at $386.11 per share. No Rule 10b5-1 trading plan is reported.
BIO-RAD LABORATORIES, INC. (symbol: BIO) is the issuer of record for a Form 4 filing submitted to the SEC.
BIO-RAD LABORATORIES, INC. (symbol: BIO) is the issuer of record for a Form 4 filing submitted to the SEC.
BIO-RAD LABORATORIES, INC. (BIO) reported insider equity activity by executive Eva Anette Engelhardt, EVP and President, CDG. On September 4, 2026 she received a grant of 4,313 restricted stock units. On September 5–6, 2026, a total of 2,179 RSUs vested and converted into Class A common shares, with 854 shares delivered or withheld to pay the exercise price or tax liability at $386.11 per share. No Rule 10b5-1 trading plan is reported.
BIO-RAD LABORATORIES, INC. (symbol: BIO) is the issuer of record for a Form 4 filing submitted to the SEC.
BIO-RAD LABORATORIES, INC. (BIO) reported that executive vice president and general counsel Courtney C. Enloe received and settled equity awards in Bio-Rad Class A common stock. On September 4, 2026, Enloe was granted 2,876 restricted stock units, each representing a contingent right to one Class A share, vesting over four years. On September 5 and 6, 2026, a total of 1,453 restricted stock units vested and were converted into an equal number of Class A shares; 551 shares were delivered or withheld at $386.11 per share for payment of exercise price or tax liability. No Rule 10b5-1 plan is reported.
BIO-RAD LABORATORIES, INC. (BIO) reported that executive vice president Rajat Mehta exercised restricted stock units into Bio-Rad Class A common stock and had shares withheld to cover exercise price or tax obligations. On September 5, 2026, he converted RSUs into 456 and 1,370 shares of Class A stock, with 233 and 504 shares, respectively, delivered or withheld at $386.11 per share for exercise price or tax liability. On September 4, 2026, he received a grant of 4,601 restricted stock units that each represent a contingent right to one share of Class A stock and vest over four years.
BIO-RAD LABORATORIES, INC. (symbol: BIO) is the issuer of record for a Form 4 filing submitted to the SEC.
BIO-RAD LABORATORIES, INC. (symbol: BIO) is the issuer of record for a Form 4 filing submitted to the SEC.
BIO-RAD LABORATORIES, INC. (BIO) reported that executive vice president James Barry had restricted stock units vest into Bio-Rad Class A common stock on September 1, 2026. A total of 425 shares of Class A common stock were acquired upon RSU vesting, and 154 shares were delivered or withheld to cover the exercise price or tax liability. The RSUs converted included blocks of 174 and 251 units, each representing a right to receive one share of Class A common stock. No transactions are reported as made under a Rule 10b5-1 trading plan.
BIO-RAD LABORATORIES, INC. (BIO) reported that director Allison Schwartz had restricted stock units vest and convert into Bio-Rad Class A common stock on September 1, 2026. A total of 117 shares of Class A common stock were acquired upon vesting of restricted stock units granted in 2022 and 2023.
The vesting reflects the conversion of 42 restricted stock units from a 2022 grant and 75 restricted stock units from a 2023 grant, each unit representing a contingent right to one Class A share. Of the vested shares, 43 shares were delivered or withheld to cover the exercise price or tax liability at $380.96 per share. No Rule 10b5-1 trading plan is reported for these transactions.
BIO-RAD LABORATORIES, INC. (symbol: BIO) is the issuer of record for a Form 4 filing submitted to the SEC.
Eva Anette Engelhardt, EVP and President, CDG of Bio-Rad Laboratories, had 246 Restricted Stock Units vest and convert into 246 shares of Bio-Rad Class A common stock on July 25, 2026. To satisfy tax obligations, 89 of those shares were withheld at $314.4600 per share. After this vesting event, she continues to hold 492 Restricted Stock Units, which vest over four years at 25% per year on the grant anniversary.
Bio-Rad Laboratories executive Eva Anette Engelhardt, EVP and President of the Clinical Diagnostics Group, reported an open-market sale of Bio-Rad A Common Stock. She sold 550 shares on May 11, 2026 at a price of $246.54 per share. After this transaction, she directly holds 346 shares of Bio-Rad A Common Stock.
Bio-Rad Laboratories EVP and Chief Financial Officer Roop Kalyan Lakkaraju reported routine equity compensation activity. On April 24, 2026, 1,078 shares of Class A common stock were acquired upon vesting of restricted stock units and converted from derivative form.
To cover tax obligations, 420 shares were disposed of through a tax-withholding transaction at $287.84 per share, leaving 2,563.895 Class A shares held directly. The filing also notes 2,156 restricted stock units remaining outstanding and references a prior 4,311-unit RSU grant vesting in four annual installments.
BIO-RAD LABORATORIES, INC. executive vice president and general counsel Courtney C. Enloe reported routine equity compensation activity. On April 24, she acquired 186 shares of Bio-Rad Class A common stock upon the vesting and conversion of restricted stock units, then had 77 shares withheld to cover tax obligations. These transactions increased her direct holdings to 826.777 Class A shares and reduced her restricted stock unit balance to 372 units from an original 744-unit grant scheduled to vest in four equal annual installments.
Hinckley Greg K reported acquisition or exercise transactions in this Form 4 filing.
Bio-Rad Laboratories director Greg K. Hinckley increased his direct equity stake through routine equity compensation. On April 21, 2026, 407 restricted stock units vested and were settled into 407 shares of Bio-Rad Class A common stock. Following this settlement, Hinckley directly held 1,215 shares of Class A common stock.
On the same date, he received a new grant of 369 restricted stock units, each representing a contingent right to one share of Bio-Rad Class A common stock. These units will vest 100% on the earlier of the first anniversary of the grant date or the company’s next annual meeting of stockholders.
Bio-Rad Laboratories director Melinda Litherland reported routine equity compensation activity. She exercised 407 restricted stock units into 407 shares of Bio-Rad Class A common stock, bringing her direct common stock holdings to 715 shares.
On the same date, she received a new grant of 369 restricted stock units, each representing a right to one share of Class A common stock. These new units will vest 100% on the earlier of the first anniversary of the grant date or the date of the company’s next annual meeting of stockholders, aligning her compensation with future company performance and governance milestones.
Bio-Rad Laboratories director Jeffrey L. Edwards exercised restricted stock units into Bio-Rad Class A common shares and received a new equity award. He acquired 407 shares of Bio-Rad A Common Stock upon vesting of restricted stock units, bringing his direct holdings to 715 shares.
At the same time, 407 Restricted Stock Units were fully converted, leaving no remaining units from that grant. Edwards was also granted 369 new Restricted Stock Units, each representing a contingent right to receive one share of Bio-Rad Class A common stock, vesting 100% on the earlier of the first anniversary of the grant date or the company’s next annual meeting of stockholders.
BIO-RAD LABORATORIES, INC. director Arnold A. Pinkston reported routine equity compensation activity. He acquired 407 shares of Bio-Rad Class A common stock upon vesting of restricted stock units, bringing his direct common stock holdings to 715 shares after the transaction.
The filing also shows 407 restricted stock units were fully settled, reducing that RSU position to zero. In addition, he received a new grant of 369 restricted stock units, each representing one share of Class A common stock, which will vest 100% on the earlier of the first anniversary of the grant date or the company’s next annual meeting of stockholders.
Bio‑Rad Laboratories (BIO) reported an insider transaction by its EVP, President, LSG. On 11/06/2025, the officer sold 699.873 shares of Bio‑Rad A Common Stock at a weighted average price of $306.182, executed in multiple trades between $306.104 and $306.230.
Following the sale, the reporting person directly beneficially owns 509.682 shares.
Bio-Rad Laboratories (BIO) reported an insider equity event by its President & COO. On 10/24/2025, 1,869 shares of Class A common stock were acquired at $0 upon the vesting of restricted stock units, followed by a disposition of 950 shares under code F at $339.75 per share. Following these transactions, 919 Class A shares are held directly.
The related RSU line shows 1,869 underlying shares delivered and 5,609 RSUs remaining outstanding. The RSUs vest over four years at 25% per year on the yearly anniversary of the grant.